<DOC>
	<DOCNO>NCT02438098</DOCNO>
	<brief_summary>Until ist systematic investigation pharmacokinetic parameter Rivaroxaban obese patient undergo bariatric surgery . The aim study investigate pharmacokinetic pharmacodynamic parameter rivaroxaban obese patient bariatric surgery . Patients receive day surgical intervention first dose Rivaroxaban ( 10mg ) . During follow 24 hour , 9 blood sample take . The second tablet Rivaroxaban administer third postoperative day , follow 9 blood sample next 24 hour . All blood sample take independent clinical trial part standard medical treatment hospitalization . The hospital stay extend study . The outpatient regular follow-up take place one month surgery combine last study visit .</brief_summary>
	<brief_title>Rivaroxaban Bariatric Surgery</brief_title>
	<detailed_description>Background The prevalence obesity morbid obesity increase worldwide become increase medical socioeconomic burden . Bariatric surgery lead sustain reduction weight associate co-morbidities . Obesity risk factor development venous thromboembolism association obesity postoperative VTE well established . The incidence symptomatic DVT PE range 0 % -5.4 % , respectively 0 % -6.4 % remain uncertain . Although overall incidence seem low , VTE represent significant cause morbidity mortality surgery . Most postdischarge VTE event occur within first 30 day surgery therefore extend chemoprophylaxis hospital discharge standard care consider especially patient classify high risk VTE . Anticoagulants recommend prevention VTE , consensus regard optimal method prophylaxis . Routine perioperative use drug low-molecular weight heparin ( LMWHs ) , intermittent pneumatic compression early mobilization currently major accept form . However , currently class I evidence provide guidance regard type dose antithrombotic prophylaxis bariatric surgery . For parenteral application example limit evidence guide dose thromboprophylaxis morbid obesity high dosage necessary , impaired absorption subcutaneous application . The knowledge effect extremely high body weight pharmacokinetic pharmacodynamics parameter bariatric surgery especially novel orally administer anticoagulant target specific factor coagulation cascade scarce . One promising therapeutic option rivaroxaban ( BAY 59-7939 , Rivaroxaban ) , orally administer direct factor Xa inhibitor approve several indication field prevention treatment thromboembolic disorder . In several type bariatric surgery procedure , sleeve gastrectomy , Roux-en-Y gastric bypass biliopancreatic diversion different part gastrointestinal tract bypass remove . This could affect absorption medication . Absorption rivaroxaban dependent site drug release GI tract . In study look administration crush tablet via tube , 29 % 56 % decrease AUC Cmax compare oral tablet report rivaroxaban granulate release proximal small intestine . The effect alter anatomy due RYGB oral drug absorption bioavailability currently unknown . Previous study focus drug like metformin , sertraline tacrolimus , yield conflicting result . In case report Mahlmann et al . absorption rivaroxaban immediate significantly impair bariatric surgery upper GI tract . However , data large patient collective available . Rivaroxaban already approve VTE prophylaxis orthopaedic patient . Up , clinical data available regard obese patient bariatric surgery . To fill gap , phase 1 clinical trial design study design allow intra-patient comparison effect bariatric surgery regard pharmacokinetic pharmacodynamics analysis . Rivaroxaban oral anticoagulant could attractive option VTE prophylaxis compare subcutaneous ( LMWH ) standard treatment bariatric surgery . Especially high-risk patient ( high BMI , history DVT , obesity hypoventilation syndrome , pulmonary hypertension , hormonal therapy , venous stasis disease , male gender , expect long operative time open approach , extend duration thromboprophylaxis hospital discharge recommend , oral therapy would attractive . Until systematic investigation pharmacokinetic parameter rivaroxaban obese patient undergo bariatric surgery . This phase I clinical trial offer unique opportunity investigate PK/PD morbidly obese patient pre post bariatric surgery . The result trial help design large trial particular patient population final goal safe efficient use rivaroxaban morbidly patient . Objective The aim study investigate pharmacokinetic pharmacodynamic parameter rivaroxaban obese patient bariatric surgery . Methods Investigation rivaroxaban AUC bariatric .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Patient schedule elective bariatric surgery : laparoscopic RouxenY gastric bypass surgery sleeve resection Patient age 18 year old BMI 35kg/m^2 high Women child bear age : willingness use double barrier contraception method study Informed Consent document signature Exclusion Criteria Intake oral anticoagulant ( phenprocoumon , acenocoumarol , dabigatran , etexilate , apixaban etc . ) 4 week prior inclusion study Application parenteral anticoagulant ( unfractionated heparin , low molecular weight heparin , heparin derivates ( fondaparinux etc . ) 4 week prior inclusion study Pharmacologic platelet inhibition 4 week prior inclusion study Known coagulation disorder ( e.g . Willebrand 's disease , haemophilia ) Evidence deep vein thrombosis pulmonary embolism personal history history first degree relative Medical condition associate increase risk VTE , i.e . active cancer disease , lupus erythematodes chronic inflammatory bowel disease Active , clinically significant bleed Congenital acquire bleed disorder Uncontrolled severe hypertension Active gastrointestinal disease potentially lead bleed disorder : oesophagitis , gastritis , gastroesophageal reflux disease , chronic inflammatory bowel disease Vascular retinopathy Bronchiectasis history pulmonary bleeding Prior stroke TIA Hereditary galactose intolerance , Lapp lactase deficiency , glucoselactose malabsorption Severe renal impairment creatinine clearance ( GFR ) &lt; 30ml/min Positive pregnancy test , pregnancy nurse woman High risk bleeding ( e.g . active ulcerative gastrointestinal disease ) Known intolerance study medication rivaroxaban Concomitant treatment strong CYP3A4 inhibitor ( e.g . ketoconazole , itraconazole , lopinavir , ritonavir , indinavir ) Concomitant treatment Pglycoprotein inhibitor weak moderate CYP3A4 inhibitor ( e.g . erythromycin , azithromycin , diltiazem , verapamil , quinidine , ranolazine , dronedarone , amiodarone , felodipine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Rivaroxaban</keyword>
	<keyword>Obesity</keyword>
	<keyword>Bariatric surgery</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>